Salvia Jain, MD
Hematology · Boston, MANPI 1417168055
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,101 of the $17,823 with a category attached, or 84.7%. Acrotech Biopharma Inc. accounts for 68.4% of it on its own, with 5 other manufacturers making up the rest.
Across 23 payments — averaging $774.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acrotech Biopharma Inc.$12K
- Secura Bio, Inc.$4K
- Daiichi Sankyo Inc.$1K
- Kyowa Kirin, Inc.$215
- Pfizer$204
- TG Therapeutics, Inc.$120
Across 10 payments — averaging $73,504 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kyowa Kirin, Inc.$260K
- Daiichi Sankyo Inc.$245K
- Acrotech Biopharma Inc.$230K
What the payments were for
- Consulting fees$15,10185%
- Speaking & faculty fees$1,87511%
- Food & beverage$8465%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acrotech Biopharma Inc. | 12 | $12,197 |
| Secura Bio, Inc. | 5 | $3,676 |
| Daiichi Sankyo Inc. | 1 | $1,410 |
| Kyowa Kirin, Inc. | 2 | $215 |
| Pfizer | 2 | $204 |
| TG Therapeutics, Inc. | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,823 in reported general payments places this provider in the 65th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopiktraDuvelisib | 15 | $1,075,507 |
| Atovaquone | 14 | $11,784 |
| Acyclovir | 33 | $803 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $98 |
| Prednisone | 34 | $97 |
Paid to pharmacies, not to this prescriber.
Other hematology in Boston
- Edward BenzBoston$747K
- David KuterBoston$543K
- Jacalyn RosenblattBoston$455K
- Lynn BryBoston$286K
- John SloanBoston$257K
- Andrew EvensBoston$217K
- Omar NadeemBoston$191K
- Nathan ConnellBoston$145K
- Jean ConnorsBoston$144K
- Heather BenjaminBoston$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.